Search
Now showing items 3561-3570 of 4397
Mapping Local Failure Following Bladder Radiotherapy According to Dose.
(ELSEVIER SCIENCE LONDON, 2022-06-09)
AIMS: To determine the relationship between local relapse following radical radiotherapy for muscle-invasive bladder cancer (MIBC) and radiation dose. MATERIALS AND METHODS: Patients with T2-4N0-3M0 MIBC were recruited to ...
Age, Period and Cohort Analysis of Smoking Prevalence in Iranian Population over a 25-Year Period.
(ACAD MEDICAL SCIENCES I R IRAN, 2021-01-01)
BACKGROUND: Current and daily smoking prevalence rates have been have investigated in several cross-sectional studies. However, analyses in terms of age-period-cohort (APC) have not been carried out. We assessed daily ...
The sequence kernel association test for multicategorical outcomes.
(WILEY, 2023-04-19)
Disease heterogeneity is ubiquitous in biomedical and clinical studies. In genetic studies, researchers are increasingly interested in understanding the distinct genetic underpinning of subtypes of diseases. However, ...
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
(AMER ASSOC CANCER RESEARCH, 2023-04-03)
PURPOSE: ALK-activating mutations are identified in approximately 10% of newly diagnosed neuroblastomas and ALK amplifications in a further 1%-2% of cases. Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) ...
Next-Generation Sequencing and Image-Guided Tissue Sampling: A Primer for Interventional Radiologists.
(Elsevier BV, 2023-03-01)
The discovery of increasing numbers of actionable molecular and gene targets for cancer treatment has driven the demand for tissue sampling for next-generation sequencing (NGS). Requirements for sequencing can be very ...
Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort.
(BMC, 2023-05-03)
BACKGROUND: Breast cancer survivors are living longer due to early detection and advances in treatment and are at increased risk for second primary cancers. Comprehensive evaluation of second cancer risk among patients ...
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
(LIPPINCOTT WILLIAMS & WILKINS, 2023-08-10)
PURPOSE: The multicenter OPTIMUM (MUKnine) phase II trial investigated daratumumab, low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) before and after autologous stem-cell transplant (ASCT) ...
DNA methylation-based classification of glioneuronal tumours synergises with histology and radiology to refine accurate molecular stratification.
(WILEY, 2023-04-01)
AIMS: Glioneuronal tumours (GNTs) are poorly distinguished by their histology and lack robust diagnostic indicators. Previously, we showed that common GNTs comprise two molecularly distinct groups, correlating poorly with ...
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.
(BMJ PUBLISHING GROUP, 2021-08-01)
BACKGROUND: Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to PD-1 inhibitors, ...
EANM enabling guide: how to improve the accessibility of clinical dosimetry.
(SPRINGER, 2023-04-22)
Dosimetry can be a useful tool for personalization of molecular radiotherapy (MRT) procedures, enabling the continuous development of theranostic concepts. However, the additional resource requirements are often seen as a ...